Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
UNC Lineberger Comprehensive Cancer Center
SWOG Cancer Research Network
National Cancer Institute (NCI)
Yale University
Radiation Therapy Oncology Group
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Incyte Corporation
M.D. Anderson Cancer Center
Bristol-Myers Squibb
Sanofi
Sanofi
Institut Bergonié
GERCOR - Multidisciplinary Oncology Cooperative Group
Sotio Biotech Inc.
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Nektar Therapeutics
AIDS Malignancy Consortium
University of Utah
Menarini Group
NuCana plc
Washington University School of Medicine
HiberCell, Inc.
US Oncology Research
Washington University School of Medicine
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
Academic and Community Cancer Research United
University of Arizona
GlaxoSmithKline
University of Cincinnati
The University of Texas Health Science Center at San Antonio
Pierre Fabre Medicament
Stanford University
Washington University School of Medicine
Pfizer
Rutgers, The State University of New Jersey
Pharmacyclics LLC.
Sumitomo Pharma America, Inc.
Bristol-Myers Squibb
Pfizer
Merck Sharp & Dohme LLC
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group